Explore stories from Atlantic Canada.
- Paris-based drugmaker Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics, Bloomberg News reported on Thursday citing people familiar with the matter.
Deliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors. A Sanofi spokesperson responded to a Reuters' request saying the company does not comment on market rumors. Mirati, whose shares rose 25.48% to $53.83, did not immediately respond to Reuters' request for a comment.
Mirati's lung cancer drug, Krazati, had received the U.S. health regulator's nod in December to treat adults with advanced lung cancer.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘Sell the News’ Strikes Again After Debut of Ether Futures ETFs - BNN BloombergEther is underperforming in the cryptocurrency market after the inaugural ETFs featuring futures for the second-biggest digital currency began trading in the US on Monday.
Read more »
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drugBy Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop ...
Read more »
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drugBy Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop ...
Read more »